broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K72951360-001-01-4 | ACH-000622 | KNS42_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | -0.122324 | 0.811244 | 0.638894 | 0.785485 | 1.60025 | 1.221875 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000622 |
BRD-K72951360-001-01-4 | ACH-000403 | NCIH747_LARGE_INTESTINE | HTS002 | 1 | 0.0595 | 2.402047 | 0.400468 | 0.736716 | 0.661419 | 0.697242 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000403 |
BRD-K72951360-001-01-4 | ACH-000141 | SNU308_BILIARY_TRACT | HTS002 | 1 | 0.179112 | 4.196418 | 0.427904 | 0.750258 | 0.522191 | 0.580403 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000141 |
BRD-K72951360-001-01-4 | ACH-000988 | MFE319_ENDOMETRIUM | HTS002 | 1 | 0.002438 | 1.699342 | 0.608474 | 0.56871 | 0.150696 | 0.15113 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000988 |
BRD-K72951360-001-01-4 | ACH-000848 | JHH7_LIVER | HTS002 | 1 | 0.058381 | 2.848102 | 0.752071 | 0.610693 | 0.180955 | 0.189018 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000848 |
BRD-K72951360-001-01-4 | ACH-000785 | NCIH2126_LUNG | HTS002 | 1 | 0.009459 | 19.775732 | 0.419469 | 0.840841 | 2.102962 | 2.104994 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000785 |
BRD-K72951360-001-01-4 | ACH-000544 | OE21_OESOPHAGUS | HTS002 | 1 | 0.232908 | 5.715039 | 0.529477 | 0.753388 | 0.441679 | 0.492895 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000544 |
BRD-K72951360-001-01-4 | ACH-000982 | GP2D_LARGE_INTESTINE | HTS002 | 1 | 0.012383 | 2.805971 | 0.742334 | 0.522127 | 0.091366 | 0.092186 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000982 |
BRD-K72951360-001-01-4 | ACH-000021 | NCIH1693_LUNG | HTS002 | 1 | 0.070947 | 17.561774 | 0.515958 | 0.735349 | 0.630191 | 0.635707 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000021 |
BRD-K72951360-001-01-4 | ACH-000823 | KYSE140_OESOPHAGUS | HTS002 | 1 | 0.0476 | 1.071519 | 0.613777 | 0.70345 | 0.505435 | 0.554898 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000823 |
BRD-K72951360-001-01-4 | ACH-000915 | IPC298_SKIN | HTS002 | 1 | 0.030392 | 5.882091 | 0.82433 | 0.571402 | 0.137116 | 0.138586 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000915 |
BRD-K72951360-001-01-4 | ACH-000984 | HEC6_ENDOMETRIUM | HTS002 | 1 | 0.007451 | 8.576784 | 0.561572 | 0.58754 | 0.177283 | 0.177594 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000984 |
BRD-K72951360-001-01-4 | ACH-000579 | UACC257_SKIN | HTS002 | 1 | -0.068744 | 1.089819 | 0.59731 | 0.749197 | 0.93754 | 0.833017 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000579 |
BRD-K72951360-001-01-4 | ACH-001306 | 8305C_THYROID | HTS002 | 1 | 0.000592 | 1.805563 | 0.798373 | 0.6982 | 0.535239 | 0.53559 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-001306 |
BRD-K72951360-001-01-4 | ACH-000318 | TE10_OESOPHAGUS | HTS002 | 1 | -0.018044 | 1.153142 | 0.578202 | 0.77213 | 1.175472 | 1.139883 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000318 |
BRD-K72951360-001-01-4 | ACH-000840 | HCC366_LUNG | HTS002 | 1 | -0.040044 | 1.042154 | 0.762419 | 0.694658 | 0.539802 | 0.501336 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000840 |
BRD-K72951360-001-01-4 | ACH-000503 | BICR16_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 0.05509 | 3.645626 | 0.225858 | 0.709621 | 0.506839 | 0.523331 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000503 |
BRD-K72951360-001-01-4 | ACH-000726 | TE14_OESOPHAGUS | HTS002 | 1 | 0.018116 | 3.945231 | 0.553415 | 0.603859 | 0.199384 | 0.201258 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000726 |
BRD-K72951360-001-01-4 | ACH-000919 | IM95_STOMACH | HTS002 | 1 | 0.098286 | 7.066955 | 0.564054 | 0.616736 | 0.161697 | 0.166783 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000919 |
BRD-K72951360-001-01-4 | ACH-000188 | SCC25_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | -0.029382 | 0.859191 | 0.459959 | 0.551323 | 0.130648 | 0.122247 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000188 |
BRD-K72951360-001-01-4 | ACH-000618 | SNU1041_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 0.081068 | 1.778906 | 0.770784 | 0.689458 | 0.377134 | 0.416566 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000618 |
BRD-K72951360-001-01-4 | ACH-000822 | SKMEL24_SKIN | HTS002 | 1 | -0.040578 | 0.972364 | 0.703065 | 0.674644 | 0.445936 | 0.411549 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000822 |
BRD-K72951360-001-01-4 | ACH-000292 | NCIH841_LUNG | HTS002 | 1 | 0.035592 | 4.60369 | 0.878423 | 0.563588 | 0.12385 | 0.125853 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000292 |
BRD-K72951360-001-01-4 | ACH-000827 | WM793_SKIN | HTS002 | 1 | 0.000437 | 0.99257 | 0.746413 | 0.597391 | 0.204285 | 0.204464 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000827 |
BRD-K72951360-001-01-4 | ACH-000411 | 769P_KIDNEY | HTS002 | 1 | 0.001549 | 1.055522 | 0.765693 | 0.625157 | 0.266689 | 0.267474 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000411 |
BRD-K72951360-001-01-4 | ACH-000139 | PANC0327_PANCREAS | HTS002 | 1 | 0.024127 | 6.356673 | 0.426203 | 0.583281 | 0.158616 | 0.159855 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000139 |
BRD-K72951360-001-01-4 | ACH-000569 | ISTMES1_PLEURA | HTS002 | 1 | -0.011302 | 0.553297 | 0.619571 | 0.560699 | 0.153779 | 0.147691 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000569 |
BRD-K72951360-001-01-4 | ACH-000741 | UBLC1_URINARY_TRACT | HTS002 | 1 | 0.00685 | 2.242985 | 0.615165 | 0.541952 | 0.113837 | 0.114539 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000741 |
BRD-K72951360-001-01-4 | ACH-000278 | COV362_OVARY | HTS002 | 1 | 0.04175 | 1.698786 | 0.707518 | 0.55672 | 0.112337 | 0.118253 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000278 |
BRD-K72951360-001-01-4 | ACH-000425 | UACC62_SKIN | HTS002 | 1 | 0.000117 | 1.331958 | 0.893303 | 0.58431 | 0.177519 | 0.17755 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000425 |
BRD-K72951360-001-01-4 | ACH-000013 | ONCODG1_OVARY | HTS002 | 1 | 0.029705 | 4.633912 | 0.59958 | 0.563307 | 0.126837 | 0.128525 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000013 |
BRD-K72951360-001-01-4 | ACH-000231 | KALS1_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.000689 | 1.075566 | 0.763501 | 0.613975 | 0.239092 | 0.239399 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000231 |
BRD-K72951360-001-01-4 | ACH-000730 | SKMEL5_SKIN | HTS002 | 1 | -0.00004 | 1.301401 | 0.539757 | 0.626062 | 0.267254 | 0.267238 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000730 |
BRD-K72951360-001-01-4 | ACH-000500 | SNU46_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 0.00172 | 29.248443 | 0.454661 | 0.846149 | 2.241239 | 2.241503 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000500 |
BRD-K72951360-001-01-4 | ACH-000222 | ASPC1_PANCREAS | HTS002 | 1 | 0.00036 | 2.328774 | 0.693413 | 0.715019 | 0.629263 | 0.629458 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000222 |
BRD-K72951360-001-01-4 | ACH-000477 | MALME3M_SKIN | HTS002 | 1 | -0.135639 | 0.991395 | 0.328265 | 0.795114 | 1.592318 | 1.249926 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000477 |
BRD-K72951360-001-01-4 | ACH-000223 | HCC1937_BREAST | HTS002 | 1 | 0.053799 | 1.733291 | 0.603604 | 0.720998 | 0.574212 | 0.61319 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000223 |
BRD-K72951360-001-01-4 | ACH-000495 | TUHR4TKB_KIDNEY | HTS002 | 1 | 0.068918 | 1.356692 | 0.735965 | 0.606998 | 0.166802 | 0.186071 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000495 |
BRD-K72951360-001-01-4 | ACH-000434 | NCIH1915_LUNG | HTS002 | 1 | 0.000491 | 1.007166 | 0.599637 | 0.673167 | 0.43584 | 0.436265 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000434 |
BRD-K72951360-001-01-4 | ACH-000744 | NCIH1623_LUNG | HTS002 | 1 | 0.059676 | 5.157024 | 0.723261 | 0.565606 | 0.113004 | 0.115823 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000744 |
BRD-K72951360-001-01-4 | ACH-000107 | CAPAN2_PANCREAS | HTS002 | 1 | -0.057667 | 1.292382 | 0.639316 | 0.786281 | 1.327819 | 1.220278 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000107 |
BRD-K72951360-001-01-4 | ACH-000516 | CAL78_BONE | HTS002 | 1 | 0.092981 | 7.951168 | 0.410705 | 0.692879 | 0.374087 | 0.383893 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000516 |
BRD-K72951360-001-01-4 | ACH-000182 | SNU869_BILIARY_TRACT | HTS002 | 1 | 0.01877 | 2.143185 | 0.665232 | 0.606398 | 0.203943 | 0.207617 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000182 |
BRD-K72951360-001-01-4 | ACH-000898 | SNU719_STOMACH | HTS002 | 1 | 0.006796 | 11.769948 | 0.717863 | 0.707691 | 0.574984 | 0.575653 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000898 |
BRD-K72951360-001-01-4 | ACH-000040 | U118MG_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.005698 | 1.832421 | 0.359927 | 0.752897 | 0.902619 | 0.908282 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000040 |
BRD-K72951360-001-01-4 | ACH-000808 | HUH28_BILIARY_TRACT | HTS002 | 1 | 0.000386 | 1.195024 | 0.703835 | 0.663891 | 0.389239 | 0.389491 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000808 |
BRD-K72951360-001-01-4 | ACH-000447 | NCIH2228_LUNG | HTS002 | 1 | 0.084405 | 6.449414 | 0.655339 | 0.703795 | 0.4331 | 0.445696 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000447 |
BRD-K72951360-001-01-4 | ACH-000715 | SNU1214_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 0.00575 | 8.014464 | 0.560095 | 0.708269 | 0.579977 | 0.580814 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000715 |
BRD-K72951360-001-01-4 | ACH-000186 | NCIH2444_LUNG | HTS002 | 1 | 0.027104 | 16.053464 | 0.297406 | 0.580832 | 0.152838 | 0.15337 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000186 |
BRD-K72951360-001-01-4 | ACH-000542 | HEYA8_OVARY | HTS002 | 1 | 0.016033 | 0.866972 | 0.669277 | 0.519471 | 0.087767 | 0.091129 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000542 |
BRD-K72951360-001-01-4 | ACH-000943 | RKO_LARGE_INTESTINE | HTS002 | 1 | 0.000724 | 1.28148 | 0.639263 | 0.595877 | 0.198445 | 0.198669 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000943 |
BRD-K72951360-001-01-4 | ACH-000174 | CAL62_THYROID | HTS002 | 1 | 0.014288 | 1.612489 | 0.92999 | 0.620853 | 0.239656 | 0.244004 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000174 |
BRD-K72951360-001-01-4 | ACH-000393 | HLF_LIVER | HTS002 | 1 | 0.007845 | 2.898708 | 0.56171 | 0.625802 | 0.257337 | 0.258745 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000393 |
BRD-K72951360-001-01-4 | ACH-000018 | T24_URINARY_TRACT | HTS002 | 1 | -0.053897 | 1.064534 | 0.823688 | 0.779137 | 1.297195 | 1.178261 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000018 |
BRD-K72951360-001-01-4 | ACH-000906 | ES2_OVARY | HTS002 | 1 | 0.063736 | 6.093192 | 0.88807 | 0.69113 | 0.407075 | 0.416288 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000906 |
BRD-K72951360-001-01-4 | ACH-000784 | KYSE70_OESOPHAGUS | HTS002 | 1 | 0.122258 | 1.233977 | 0.645328 | 0.661685 | 0.239263 | 0.300303 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000784 |
BRD-K72951360-001-01-4 | ACH-000265 | KP4_PANCREAS | HTS002 | 1 | 0.128518 | 2.474086 | 0.657133 | 0.578684 | 0.091737 | 0.103443 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000265 |
BRD-K72951360-001-01-4 | ACH-000880 | AGS_STOMACH | HTS002 | 1 | 0.086875 | 2.307433 | 0.903315 | 0.564577 | 0.097804 | 0.106237 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000880 |
BRD-K72951360-001-01-4 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | HTS002 | 1 | 0.000926 | 1.208224 | 0.89977 | 0.605413 | 0.218134 | 0.218469 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000961 |
BRD-K72951360-001-01-4 | ACH-000847 | HGC27_STOMACH | HTS002 | 1 | -0.000843 | 5.821328 | 0.665268 | 0.534515 | 0.109206 | 0.109175 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000847 |
BRD-K72951360-001-01-4 | ACH-000896 | 647V_URINARY_TRACT | HTS002 | 1 | 0.003342 | 2.259444 | 0.697067 | 0.613813 | 0.232822 | 0.233514 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000896 |
BRD-K72951360-001-01-4 | ACH-000685 | L33_PANCREAS | HTS002 | 1 | 0.004882 | 1.721817 | 0.494727 | 0.639048 | 0.296424 | 0.298118 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000685 |
BRD-K72951360-001-01-4 | ACH-000376 | SF295_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.045195 | 1.108031 | 0.368141 | 0.702013 | 0.49933 | 0.543902 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000376 |
BRD-K72951360-001-01-4 | ACH-000428 | UO31_KIDNEY | HTS002 | 1 | 0.002845 | 26.026289 | 0.367337 | 0.934419 | 5.282315 | 5.283473 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000428 |
BRD-K72951360-001-01-4 | ACH-000749 | DMS273_LUNG | HTS002 | 1 | 0.011519 | 1.471078 | 0.675995 | 0.559612 | 0.132675 | 0.134794 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000749 |
BRD-K72951360-001-01-4 | ACH-000572 | G361_SKIN | HTS002 | 1 | -0.038514 | 1.078122 | 0.506626 | 0.704564 | 0.593464 | 0.553991 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000572 |
BRD-K72951360-001-01-4 | ACH-000704 | OAW42_OVARY | HTS002 | 1 | 0.017777 | 3.210111 | 0.646415 | 0.701785 | 0.525364 | 0.531322 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000704 |
BRD-K72951360-001-01-4 | ACH-000457 | CAL54_KIDNEY | HTS002 | 1 | 0.044693 | 6.770018 | 0.724812 | 0.713771 | 0.546101 | 0.553707 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000457 |
BRD-K72951360-001-01-4 | ACH-000601 | MIAPACA2_PANCREAS | HTS002 | 1 | 0.030046 | 2.551209 | 0.850087 | 0.601407 | 0.185409 | 0.189968 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000601 |
BRD-K72951360-001-01-4 | ACH-000651 | SW620_LARGE_INTESTINE | HTS002 | 1 | 0.014421 | 1.415586 | 0.863063 | 0.596627 | 0.188868 | 0.192814 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000651 |
BRD-K72951360-001-01-4 | ACH-000361 | SKHEP1_LIVER | HTS002 | 1 | 0.012405 | 1.514732 | 0.928428 | 0.544918 | 0.114347 | 0.116259 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000361 |
BRD-K72951360-001-01-4 | ACH-000842 | SW480_LARGE_INTESTINE | HTS002 | 1 | 0.022121 | 2.141384 | 0.799149 | 0.621641 | 0.234115 | 0.239115 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000842 |
BRD-K72951360-001-01-4 | ACH-000570 | YKG1_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.022939 | 10.929077 | 0.518764 | 0.701955 | 0.51811 | 0.520341 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000570 |
BRD-K72951360-001-01-4 | ACH-000396 | J82_URINARY_TRACT | HTS002 | 1 | -0.000351 | 11.592757 | 0.632674 | 0.700012 | 0.544156 | 0.544123 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000396 |
BRD-K72951360-001-01-4 | ACH-000777 | KYSE30_OESOPHAGUS | HTS002 | 1 | 0.056315 | 1.828107 | 0.832213 | 0.621686 | 0.204486 | 0.218299 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000777 |
BRD-K72951360-001-01-4 | ACH-000096 | G401_SOFT_TISSUE | HTS002 | 1 | 0.018848 | 1.794451 | 0.56363 | 0.47542 | 0.055805 | 0.057013 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000096 |
BRD-K72951360-001-01-4 | ACH-000955 | SNU407_LARGE_INTESTINE | HTS002 | 1 | 0.000276 | 1.170559 | 0.242355 | 0.662718 | 0.385551 | 0.385733 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000955 |
BRD-K72951360-001-01-4 | ACH-000940 | AN3CA_ENDOMETRIUM | HTS002 | 1 | 0.000465 | 1.463739 | 0.798345 | 0.569847 | 0.153771 | 0.153869 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000940 |
BRD-K72951360-001-01-4 | ACH-001318 | PLCPRF5_LIVER | HTS002 | 1 | 0.011983 | 3.276534 | 0.778594 | 0.547976 | 0.117998 | 0.118874 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-001318 |
BRD-K72951360-001-01-4 | ACH-000332 | YAPC_PANCREAS | HTS002 | 1 | 0.01266 | 5.130449 | 0.727791 | 0.699105 | 0.519566 | 0.52217 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000332 |
BRD-K72951360-001-01-4 | ACH-000839 | SCABER_URINARY_TRACT | HTS002 | 1 | 0.006711 | 2.172983 | 0.643133 | 0.652251 | 0.334702 | 0.33679 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000839 |
BRD-K72951360-001-01-4 | ACH-000082 | G292CLONEA141B1_BONE | HTS002 | 1 | 0.303565 | 4.12332 | 0.340616 | 0.686256 | 0.126299 | 0.158418 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000082 |
BRD-K72951360-001-01-4 | ACH-000178 | HS766T_PANCREAS | HTS002 | 1 | -0.051551 | 1.555681 | 0.361949 | 0.825266 | 1.924461 | 1.806823 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000178 |
BRD-K72951360-001-01-4 | ACH-000421 | SW837_LARGE_INTESTINE | HTS002 | 1 | -0.01833 | 0.887726 | 0.628768 | 0.612216 | 0.240348 | 0.230795 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000421 |
BRD-K72951360-001-01-4 | ACH-000524 | KURAMOCHI_OVARY | HTS002 | 1 | 0.006601 | 1.216688 | 0.582693 | 0.605747 | 0.214006 | 0.216357 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000524 |
BRD-K72951360-001-01-4 | ACH-000469 | YH13_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.068035 | 3.664051 | 0.518428 | 0.713499 | 0.50631 | 0.52693 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000469 |
BRD-K72951360-001-01-4 | ACH-000153 | NCIH2052_PLEURA | HTS002 | 1 | 0.044589 | 4.994042 | 0.513127 | 0.719062 | 0.576433 | 0.587316 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000153 |
BRD-K72951360-001-01-4 | ACH-000805 | COLO679_SKIN | HTS002 | 1 | 0.001132 | 1.242432 | 0.77844 | 0.575319 | 0.162153 | 0.16245 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000805 |
BRD-K72951360-001-01-4 | ACH-000429 | A704_KIDNEY | HTS002 | 1 | 1.372071 | 0.236892 | -0.016994 | 1.144052 | 0.666505 | null | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000429 |
BRD-K72951360-001-01-4 | ACH-000108 | KP3_PANCREAS | HTS002 | 1 | 0.222759 | 8.139625 | 0.606647 | 0.768526 | 0.555751 | 0.59751 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000108 |
BRD-K72951360-001-01-4 | ACH-000939 | SKUT1_SOFT_TISSUE | HTS002 | 1 | 0.006012 | 2.583846 | 0.828772 | 0.600674 | 0.20272 | 0.203671 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000939 |
BRD-K72951360-001-01-4 | ACH-000323 | 42MGBA_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.01856 | 2.893702 | 0.838792 | 0.61725 | 0.22721 | 0.230199 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000323 |
BRD-K72951360-001-01-4 | ACH-000219 | A375_SKIN | HTS002 | 1 | 0.030407 | 1.552291 | 0.822234 | 0.590087 | 0.165465 | 0.17229 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000219 |
BRD-K72951360-001-01-4 | ACH-000903 | FTC133_THYROID | HTS002 | 1 | 0.028398 | 8.95165 | 0.654772 | 0.58103 | 0.152291 | 0.153289 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000903 |
BRD-K72951360-001-01-4 | ACH-000054 | HT1080_SOFT_TISSUE | HTS002 | 1 | 0.016372 | 0.809184 | 0.47202 | 0.47169 | 0.053707 | 0.055963 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000054 |
BRD-K72951360-001-01-4 | ACH-000302 | SNU1077_ENDOMETRIUM | HTS002 | 1 | 0.012053 | 9.738165 | 0.450935 | 0.70672 | 0.560936 | 0.562343 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000302 |
BRD-K72951360-001-01-4 | ACH-000324 | JHOC5_OVARY | HTS002 | 1 | 0.041258 | 0.839589 | 0.468188 | 0.538423 | 0.094129 | 0.104297 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000324 |
BRD-K72951360-001-01-4 | ACH-000164 | PANC1_PANCREAS | HTS002 | 1 | 0.022995 | 2.392088 | 0.506939 | 0.663719 | 0.354382 | 0.361426 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000164 |
BRD-K72951360-001-01-4 | ACH-000549 | SNU1076_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 0.001825 | 2.928031 | 0.752158 | 0.694553 | 0.513317 | 0.513959 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000549 |
BRD-K72951360-001-01-4 | ACH-000650 | IGR37_SKIN | HTS002 | 1 | 0.029881 | 2.958423 | 0.834468 | 0.687843 | 0.440485 | 0.449756 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000650 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.